# Dose Response Study in Japanese Patients

> **NCT00261417** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 250 (—)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Tesaglitazar

## Key facts

- **NCT ID:** NCT00261417
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 250 (—)
- **Why stopped:** The development program has been terminated
- **Last updated:** 2009-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00261417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00261417, "Dose Response Study in Japanese Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00261417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*